Review article: Bone disease in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 4, 2004, Pages 43-49

  Schulte, C M S ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; FLUORIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DISEASE; BONE NECROSIS; CLINICAL TRIAL; DISEASE ASSOCIATION; ENTERITIS; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SENESCENCE;

ADRENAL CORTEX HORMONES; AGE FACTORS; BONE DISEASES; BONE RESORPTION; HUMANS; INFLAMMATORY BOWEL DISEASES; LIFE STYLE; MALABSORPTION SYNDROMES; RISK FACTORS; SEX FACTORS; VITAMIN D DEFICIENCY;

EID: 4844223994     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841.
2. Compston JE. Osteoporosis in inflammatory bowel disease. Gut 2003; 52: 63-4.
3. Papaioannou A, Ferko NC, Adachi ID. All patients with inflammatory bowel disease should have bone density assessment. Pro Inflamm Bowel Dis 2001; 7: 158-62.
4. Vestergaard P, Krough K, Rejnmark L, et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 176-81.
5. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-9.
6. Schulte CM, Dignass AU, Goebell H, et al. Genetic factors determine the extent of bone loss in inflammatory bowel disease. Gastroenterology 2000; 119: 909-20.
7. Andreassen H, Hylander E, Rix M. Gender, age and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999; 94: 824-8.
8. Bernstein CN, Leslie WD, Taback SP. Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory disease. Am J Gastroenterol 2003; 98: 1094-100.
9. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.
10. Bernstein CN, Blanchard JF, Metge C, et al. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003; 98: 1797-801.
11. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16: 348-60.
12. Redlich K, Hayer S, Maier A, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46: 785-92.
13. Viereck V, Emons G, Lauck V, et al. Bisphosphonates. pamidronate and zoledronic acid stimulate osteoprotegerin production by primary osteoblasts. Biochem Biophys Res Commun 2002; 291: 680-6.
14. Cranney A, Guyatt G, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8.
15. Heaney RP. Bone mass, bone fragility and the decision to treat. J Am Med Assoc 1998; 280: 2119-20.
16. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9.
17. Wallach S, Sohen S, Reid DM. Effects of risedronate treatment on bone density and vertebral fractures in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277-85.
18. Hanauer SB. New steroids for IBD: progress report. Gut 2002; 51: 182-3.
19. Haderslev KV, Tjellesen L, Sorensen HA, et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639-46.